Introduction

Biomedical Reports

2049-9434 2049-9442

D.A. Spandidos

BR-23-5-02048

10.3892/br.2025.2048

Articles

Puerariae radix flavones induce apoptosis in bladder cancer T24 cells via the FAS/TNFR1 pathway: A potential therapeutic candidate

Dong

Jing

1 Guo

Yupeng

1 Ji

Tao

1 Guan

Hongjun

1 Ma

Yanbin

2 Rong

Shengzhong

1College of Public Health, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011, P.R. China 2College of Science, Harbin University of Science and Technology, Harbin, Heilongjiang 150080, P.R. China

Correspondence to: Dr Shengzhong Rong, College of Public Health, Mudanjiang Medical University, 3 Tongxiang Street, Aimin, Mudanjiang, Heilongjiang 157011, P.R. China sz_rong@yeah.net

112025

27082025

23 5

170

26 04 2025 14 08 2025

2025

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Puerariae radix flavones (PRFs), bioactive components derived from the Pueraria lobata plant, exhibit anti-inflammatory and anti-tumor properties. However, their therapeutic potential for bladder cancer remains poorly understood. The present study aimed to investigate the anti-tumor effects and molecular mechanisms underlying the effects of PRF on human bladder cancer T24 cells. In vitro experiments were performed out in PRF-treated T24 cells, and the effects of PRF were assessed through MTT assay, acridine orange/ethidium bromide staining, agarose gel electrophoresis, reverse transcription-quantitative PCR and ELISA. PRF significantly inhibited T24 cell proliferation via inducing apoptosis through the extrinsic apoptosis pathway. Mechanistically, PRF induced FAS receptor/tumor necrosis factor-α receptor, enhanced the activity of cysteinyl aspartate-specific protease-3 and downregulated NF-κB. To the best of our knowledge, the present study is the first to demonstrate that PRF could suppress the proliferation of human bladder cancer T24 cells and to elucidate its underlying molecular mechanism. These findings may provide novel insights into PRF as a promising therapeutic agent for bladder cancer treatment.

Puerariae radix flavone T24 bladder cancer cell apoptosis death receptor pathway caspase-3 NF-κB

Funding: The present study was supported by the National Natural Science Foundation of China (grant nos. 82173568, 81703269, 81973097 and 82273687), the Natural Science Foundation of Heilongjiang Province (grant no. LH2023H054), the Huoju Plan Research Foundation of Mudanjiang Medical University (grant no. 2022-MYHJ-014), the Special Program for Supervisor Scientific Research of Mudanjiang Medical University (grant nos. YJSZX2022137 and YJSZX2022141), the Administration of Science & Technology Foundation of Mudanjiang (grant nos. HT2022NS112 and HT2022NS113), the Scientific Research Project of the Health Commission of Heilongjiang Province (grant no. 20221212060609) and the Fundamental Research Funds for the Universities of Heilongjiang Province (grant no. 2022-KYYWFMY-0712).

Introduction

Bladder cancer (BC) is one of the most prevalent malignancies globally, with an estimated 613,791 new cases reported in 2022 according to GLOBOCAN 2022(1). Clinically, BC is categorized into three main subtypes, namely non-muscle-invasive (NMI), MIB and metastatic BC (2). While NMIBC accounts for ~80% of initial BC diagnoses and is associated with a favorable 5-year survival rate >90% (3), it has a 1-year recurrence rate of 15-61%, and a 5-year recurrence rate of 31-78% (4). Its high recurrence rate imposes substantial healthcare burdens (5-9). By contrast, MIBC and metastatic BC, accounting for ~25% of all diagnoses, are associated with aggressive progression and poorer prognosis (10). Disparities in BC outcomes are associated with ethnicity, sex and socioeconomic factors (11-16). Management strategies for NMIBC and MIBC include transurethral resection combined with intravesical therapies, such as mitomycin C and Bacillus Calmette-Guérin (17-21), and platinum-based neoadjuvant chemotherapy followed by radical cystectomy, respectively (10,22). However, chemotherapy resistance and toxicity underscore the need for more safe and effective therapeutic agents (22).

Pueraria spp. (Leguminosae), notably P. lobata and P. thomsonii, are medicinal plants that are widely distributed in East Asia. The 2020 edition of the Chinese Pharmacopoeia recognizes the dried roots (radix) of Pueraria as a source of bioactive compounds, particularly isoflavonoids such as puerarin, which are the primary active components of Puerariae radix flavones (PRF) (23-43). Previous studies demonstrated that PRF exhibit multifaceted pharmacological properties, such as anti-cancer effects, in colon (HT-29 cells), cervical (HeLa cells), liver (SMMC-7721 cells) and breast cancer (HS578T, MDA-MB-231 and MCF-7 cells), acute promyelocytic leukemia (NB4 cells), neuroblastoma (SHSY5Y cells), pancreatic carcinoma (BxPC-3 cells) and lung cancer (A549 cells) (44-48). Despite these findings, the anti-tumor activity of PRF against BC remains unexplored.

T24 cells serve as the preferred model for research on invasion, metastasis and drug resistance mechanisms in BC. Their intrinsic cisplatin resistance (49) makes T24 cells a classical system for exploring drug mechanisms of action (50) that are widely used in fundamental BC research (51,52). Moreover, in natural compound anticancer mechanism studies, most researchers employ single-cell models to investigate mechanisms of action (47,50). Therefore, the present study investigates the effects of PRF on human bladder cancer T24 cells and its underlying molecular mechanisms.

Materials and methods <sec> <title>Drug preparation and cell culture

PRF (Taobao; purity ≥80%) was dissolved in anhydrous ethanol to prepare an 8,000 µg/ml stock solution, which was stored at 4˚C. T24 cells (Procell Life Science & Technology Co., Ltd.) were authenticated by STR profiling (Mayo Clinic Cytogenetics Core) and confirmed to be free of mycoplasma contamination. Cells were cultured in RPMI-1640 (Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Shanghai VivaCell Biosciences, Ltd.) at 37˚C in a humified atmosphere with 5% CO₂. Cells were maintained at a density of <1x10⁶ cells/ml and used within three passages.

MTT assay

Cells (5x10³/well) in 200 µl medium were treated with 0, 25, 50, 100 and 200 µg/ml PRF at 37˚C for 24 or 48 h. Following treatment with MTT reagent (Sigma-Aldrich, Merck KGaA), cells were incubated at 37˚C for an additional 4 h. Finally, the absorbance at 490 nm was measured using a microplate reader.

Acridine orange/ethidium bromide (AO/EB) fluorescence staining

Following treatment with 0-200 µg/ml PRF at 37˚C for 24 or 48 h, T24 cells were stained with AO/EB (Sigma-Aldrich, Merck KGaA) in the dark at room temperature for 5 min. Images were captured under a fluorescence microscope (magnification, x200).

DNA ladder assay

Following incubation with PRF (0, 50, 100 and 200 µg/ml) at 37˚C for 24 or 48 h, 1x10⁶ T24 cells were collected. Subsequently, genomic DNA was extracted from untreated and PRF-treated cells using the Apoptosis DNA Ladder Extraction kit (cat. no. #C0007; Beyotime Institute of Biotechnology) according to the manufacturer's instructions. Finally, 5 µl DNA (containing 1 µg DNA) was mixed with 6X Loading Buffer and loaded onto a 1% agarose gel prepared in TBE buffer containing 0.5 µg/ml ethidium bromide (EB; Thermo Fisher Scientific, Inc.). Electrophoresis was performed at a constant voltage of 100 V for 30 min. DNA bands were visualized under UV irradiation (302 nm) using a gel imaging system. Caution: Ethidium bromide is a mutagenic agent. All procedures were conducted with nitrile gloves, and waste was disposed as hazardous material.

Reverse transcription-quantitative (RT-q)PCR

Following the manufacturer's protocols, total RNA was extracted from cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and reverse-transcribed into cDNA using the Transcriptor First Strand cDNA synthesis kit (cat. no. #4897030001; Roche Diagnostics). cDNA amplification was performed in triplicate with the FastStart Universal SYBR Green Master (ROX) kit (cat. no. #4913850001; Roche Diagnostics) on an ABI Prism 7500 system (Thermo Fisher Scientific, Inc.). The primer sequences for BCL2, BAX, FAS receptor (FAS), FAS ligand (FASL), tumor necrosis factor receptor 1 (TNFR1), tumor necrosis factor-α (TNF-α), cysteinyl aspartate-specific protease-3 (CASP3), NF-κB and GAPDH are listed in Table I. The primers were designed and synthesized by Sangon Biotech Co., Ltd.

The thermocycling conditions were as follows: Initial denaturation at 50˚C for 2 min and 95˚C for 10 min, followed by 45 cycles of 95˚C for 15 sec and 60˚C for 1 min. The relative mRNA expression levels were calculated using the 2^-^ΔΔ^Cq method (53).

ELISA

Following incubation with PRF (0, 50, 100 and 200 µg/ml) at 37˚C for 24 or 48 h, cells and culture medium were collected. The protein expression levels of FAS and TNF-α were quantified in T24 cells and culture supernatant using the corresponding ELISA kits (cat. nos. #JL14207 and #JL10208, respectively; both Shanghai Future Industrial Co., Ltd.) according to the manufacturer's instructions.

Statistical analysis

All data were analyzed using SPSS Statistics (version 25; IBM Corporation) or GraphPad Prism (version 8.1; GraphPad Software, Inc.; Dotmatics). Experiments were performed in triplicate, and all data are presented as the mean ± SD. Data were analyzed using two-way repeated-measures ANOVA followed by Dunnett's post hoc tests. P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>PRF inhibits the viability of T24 cells

MTT assay demonstrated that PRF could significantly inhibit the viability of T24 cells in a time- and dose-dependent manner (Fig. 1A). The inhibition rate in cells treated with 200 µg/ml PRF for 12 h was significantly higher compared with that in the control group (Fig. 1A). Additionally, the inhibition rates of cells exposed to 50, 100 and 200 µg/ml PRF for 24 h were all increased compared with the control group. Consistently, at 48 and 72 h, the inhibition rates in the 100 and 200 µg/ml PRF-treated groups were significantly higher compared with the control group. PRF exhibited a clear dose- and time-dependent inhibitory effect on cell viability, with inhibition increasing with enhanced concentration and exposure duration (Fig. 1B). Significant differences in inhibition rates were observed between time points (12, 24, 48 and 72 h).

Morphological changes in T24 cells treated with PRF

AO/EB staining revealed distinct apoptotic progression in T24 cells (Fig. 2). Increasing PRF concentrations induced a progressive fluorescence shift from green to orange-red emission. Morphologically, cells progressed from intact plasma membranes with uniform chromatin distribution to display early apoptotic hallmarks (cellular shrinkage, nuclear condensation, and apoptotic body formation) and late-stage apoptosis typified by membrane rupture, chromatin fragmentation, and nuclear dissolution. Control cells exhibited a uniform green staining (Fig. 2A and E). However, 50 µg/ml PRF induced early apoptotic features, such cell shrinkage, condensed nuclei and apoptotic bodies (Fig. 2B and F). Additionally, higher PRF concentrations (100-200 µg/ml) induced features of late apoptosis, including enhanced membrane permeability, chromatin fragmentation (orange/red staining) and nuclear disintegration (Fig. 2C, D, G and H). Notably, 100-200 µg/ml PRF exposure for 24-48 h promoted concentration- and time-dependent morphological alterations, characteristic of late-stage apoptosis.

Assessment of DNA fragmentation in T24 cells following PRF treatment

The DNA ladder assay showed no apoptotic fragmentation in T24 cells treated with PRF (0-200 µg/ml) for 24-48 h, thus suggesting that PRF-induced apoptosis was triggered via a DNA fragmentation-independent pathway (Fig. 3).

PRF modulates the expression of apoptosis-related genes

RT-qPCR demonstrated that treatment with 100 or 200 µg/ml PRF for 24 h upregulated FAS (2.0- and 2.3-fold, respectively), FASL (48.9- and 15.2-fold, respectively), TNF-α (1.4- and 2.2-fold, respectively) and CASP3 (2.1- and 1.8-fold, respectively; Fig. 4A-C and E). However, the expression of TNFR1 only significantly increased in cells treated with 200 µg/ml PRF (1.2-fold; Fig. 4D). No significant changes were observed in the mRNA expression of NF-κB, BCL-2 and BAX (Fig. 4F-H). Additionally, treatment with PRF for 48 h slightly upregulated FAS at 100 and 200 µg/ml (1.3- and 1.2-fold, respectively; Fig. 4A), and markedly upregulated TNF-α at 200 µg/ml (1.6-fold; Fig. 4C). By contrast, FASL (0.5-fold at 100 µg/ml), TNFR1 (0.8-fold at 200 µg/ml), and NF-κB (0.8- and 0.6-fold at 100 and 200 µg/ml, respectively) were significantly downregulated (Fig. 4B, D and F). No significant alterations were detected in the mRNA expression of CASP3, BCL-2 and BAX (Fig. 4E, G and H).

PRF modulates the protein expression of FAS and TNF-α

ELISA showed that treatment with PRF for 24 h resulted in a dose-dependent increase of intracellular FAS and TNF-a protein levels (50-200 µg/ml; Fig. 5A and C). By contrast, the secreted levels of FAS were reduced in the culture supernatant (50-200 µg/ml; Fig. 5B). In addition, the secreted levels of TNF-α were elevated only at 50 µg/ml (Fig. 5D). Furthermore, T24 cell exposure to PRF for 48 h dose-dependently increased the intracellular and secreted levels of FAS (50-200 µg/ml; Fig. 5A and B). However, intracellular and secreted TNF-α levels were only significantly elevated at 50 µg/ml (Fig. 5C and D).

Discussion

The present study demonstrated that treatment with PRF for 24 and 48 h significantly inhibited T24 cell viability in a dose- and time-dependent manner, with the most pronounced effects observed at 100 and 200 µg/ml. The ability of PRF to promote T24 cell apoptosis was shown by flow cytometry in our previous study (54). Here, morphological examination revealed characteristic apoptotic features, including early-stage membrane shrinkage and late-stage apoptotic body formation. Notably, the absence of DNA laddering suggested that PRF induced apoptosis via a non-canonical DNA fragmentation pathway. Although no direct evidence currently demonstrates PRF-induced apoptosis via this mechanism in other cancer cells, it is hypothesized that negative DNA fragmentation results may contribute to the underreporting of such findings. Consistent with this observation, our team previously demonstrated flavonoid compounds extracted from Galium verum L. likewise yield negative DNA fragmentation results when inducing apoptosis in HepG2 hepatocellular carcinoma cells (unpublished data). The hypothesis that PRF induces apoptosis through non-classical DNA fragmentation pathways is based on the T24 cell model. To the best of our knowledge, the present study is the first to report a non-canonical DNA fragmentation route during PRF-induced apoptosis in T24 cells.

PRF treatment significantly upregulated FAS, FASL, TNFR1, TNFα and CASP3 in T24 cells, while NF-κB was downregulated. mRNA expression levels of both BCL2 and BAX remained unchanged, indicating that PRF-mediated apoptosis in T24 cells may involve the coordinated regulation of FAS, FASL, TNFR1, TNFα, CASP3 and NF-κB expression dynamics (Fig. 6).

Binding of FASL to its receptor induces receptor trimerization and activation (55,56). Subsequently, activated FAS can recruit Fas-associated death domain (FADD), which undergoes conformational changes that allow it to bind and cleave procaspase-8, promoting the formation of the death-inducing signaling complex (DISC). Within this complex, activated caspase-8 propagates the apoptotic cascade via cleaving and activating caspase-3 (55,56). Here, the pronounced upregulation of FAS, FASL and CASP3, accompanied by the increased intracellular FAS protein levels, supported the activation of the extrinsic apoptotic pathway. Protein expression levels of FAS were markedly decreased in cell supernatant following treatment with PRF for 24 h, and significantly elevated at 48 h. During early apoptosis, FAS proteins may aggregate and bind to the plasma membrane, leading to elevated intracellular FAS levels. In late apoptosis, loss of plasma membrane integrity may facilitate the release of membrane-bound FAS proteins into the culture medium in a soluble form (57-59), resulting in the observed increase in soluble FAS protein levels at 48 h.

DISC-associated caspase-8 can undergo auto-proteolysis to activate caspase-8, which cleaves interacting domain death agonist (Bid) into truncated (t)Bid (56,60). tBid can translocate to mitochondria, thus perturbing the equilibrium between pro-apoptotic and anti-apoptotic Bcl-2 family members (60-62). However, the lack of alterations in the mRNA expression levels of BCL2 and BAX indicated that the PRF-induced cell apoptosis may occur independently of the mitochondrial pathway. Nandana et al (50) confirmed that Brucein D (a bioactive quassinoid compound isolated from Brucea javanica fruit) induces apoptosis in T24 cells by regulating the Bcl-2/Bax pathway, exhibiting the classical DNA ladder feature. Conversely, the typical DNA laddering would not be expected in apoptotic mechanisms independent of the Bcl-2/Bax pathway. This was further reinforced by the absence of characteristic DNA ladder fragmentation, supporting extrinsic apoptotic pathway involvement.

In parallel with the FAS pathway, TNFα binding to TNFR1 disrupts its interaction with the inhibitory protein silencer of death domains, enabling the recruitment of TNF receptor-associated death domain (TRADD) through the intracellular death domain (63-67). TRADD interacts with FADD, activating procaspase-8 to caspase-8, which cleaves caspase-3. In the present study, the concurrent upregulation of TNFR1, TNFα and CASP3 further supported the involvement of this TNFα-driven apoptotic mechanism. In addition, the significant elevation of the TNF-α protein expression demonstrated that TNF-α may be involved in PRF-induced apoptosis in BC cells.

TRADD recruits TNFR-associated factor 2 and receptor-interacting serine/threonine-protein kinase 1, leading to the activation of the IKK complex, which degrades IκB (63,64). This process can promote the release of NF-κB, allowing its nuclear translocation and the subsequent transcription of pro-survival genes (63,64). Paradoxically, the present NF-κB downregulation indicated that PRF may suppress this survival signaling axis, thus shifting the cellular balance toward apoptosis. Although this interaction may be indirect, the inverse association between NF-κB suppression and caspase activation may provide evidence for the pro-apoptotic effects of PRF.

NF-κB exhibits biphasic regulation (68). NF-κB upregulation promotes cellular survival via transcription of pro-survival genes (63,64). However, its pathological hyperactivation promotes tumor progression and chemoresistance through the upregulation of anti-apoptotic factors and activation of survival signaling (69,70). By contrast, crosstalk between TNF-α and FAS could promote the establishment of a compensatory apoptotic axis by amplifying the activation of caspase-8 and -3, thus counteracting NF-κB-mediated cytoprotection (71). In the present study, PRF led to a biphasic modulation of NF-κB, which was characterized by transient upregulation at 24 h followed by downregulation at 48 h. The aforementioned finding was consistent with context-dependent biphasic NF-κB regulation, implicating NF-κB in PRF-induced apoptosis. These results indicated a dual role for NF-κB in T24 cells, acting as both a pro-survival mediator and a stress-responsive modulator of apoptosis.

The present study had limitations. Firstly, the antitumor effects of PRF were not validated through in vivo animal experiments. Secondly, the findings were verified solely in the T24 cell line without replication in other BC cell lines, thereby restricting the generalizability of the conclusions. Investigation of the mechanistic pathways lacked protein-level validation by western blot analysis. Fourthly, no positive control was included in the DNA ladder assay.

In conclusion, the present study demonstrated that PRF exhibited a significant inhibitory effect on the viability of BC cells (T24 cell line). This inhibitory activity displayed a time- and dose-dependent association, with more pronounced effects observed at PRF concentrations of 100 and 200 µg/ml following treatment for 24 and 48 h. Mechanistically, the results indicated that the PRF-induced apoptosis was triggered by two mechanisms, namely the death receptor-mediated pathways (FAS/TNFR1) in the absence of mitochondrial pathways and the biphasic modulation of NF-κB signaling, characterized by a switch from survival to apoptosis. Overall, these findings highlighted the therapeutic potential of PRF for the treatment of apoptosis-resistant BC.

Acknowledgements

Not applicable.

Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

Authors' contributions

JD designed the study, analyzed and interpreted data and wrote and revised the manuscript. YG and HG designed the study and analyzed data. TJ and YM analyzed data and wrote the manuscript. SR designed the study and wrote and revised the manuscript. JD and SR confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Bray

Laversanne

Sung

Ferlay

Siegel

Soerjomataram

Jemal

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA Cancer J Clin742292632024

38572751

10.3322/caac.21834

Tran

Xiao

Agarwal

Duex

Theodorescu

Advances in bladder cancer biology and therapy

Nat Rev Cancer211041212021

33268841

10.1038/s41568-020-00313-1

Katims

Tallman

Vertosick

Porwal

Dalbagni

Cha

Smith

Benfante

Herr

Response to 2 induction courses of bacillus Calmette-Guèrin therapy among patients with high-risk non-muscle-invasive bladder cancer: 5-Year follow-up of a phase 2 clinical trial

JAMA Oncol105225252024

38358761

10.1001/jamaoncol.2023.6804

Teoh

Kamat

Black

Grivas

Shariat

Babjuk

Recurrence mechanisms of non-muscle-invasive bladder cancer-a clinical perspective

Nat Rev Urol192802942022

35361927

10.1038/s41585-022-00578-1

Knowles

Hurst

Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity

Nat Rev Cancer1525412015

25533674

10.1038/nrc3817

Babjuk

Böhle

Burger

Capoun

Cohen

Compérat

Hernández

Kaasinen

Palou

Rouprêt

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016

Eur Urol714474612017

27324428

10.1016/j.eururo.2016.05.041

Berdik

Unlocking bladder cancer

Nature551S34S352017

29117159

10.1038/551S34a

James

Gore

The costs of non-muscle invasive bladder cancer

Urol Clin North Am402612692013

23540783

10.1016/j.ucl.2013.01.004

Abdollah

Gandaglia

Thuret

Schmitges

Tian

Jeldres

Passoni

Briganti

Shariat

Perrotte

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis

Cancer Epidemiol372192252013

23485480

10.1016/j.canep.2013.02.002

Witjes

Bruins

Cathomas

Compérat

Cowan

Gakis

Hernández

Linares Espinós

Lorch

Neuzillet

European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines

Eur Urol79821042021

32360052

10.1016/j.eururo.2020.03.055

Wang

Chang

Racial differences in urinary bladder cancer in the United States

Sci Rep8125212018

30131523

10.1038/s41598-018-29987-2

Schinkel

Shao

Zahm

McGlynn

Shriver

Zhu

Overall and recurrence-free survival among black and white bladder cancer patients in an equal-access health system

Cancer Epidemiol421541582016

27161431

10.1016/j.canep.2016.04.012

Kaye

Canner

Kates

Schoenberg

Bivalacqua

Do African American patients treated with radical cystectomy for bladder cancer have worse overall survival? Accounting for pathologic staging and patient demographics beyond race makes a difference

Bladder Cancer22252342016

27376141

10.3233/BLC-150041

Casey

Gross

Wisnivesky

Stensland

Galsky

The impact of regionalization of cystectomy on racial disparities in bladder cancer care

J Urol19436412015

25623748

10.1016/j.juro.2015.01.076

Dobruch

Daneshmand

Fisch

Lotan

Noon

Resnick

Shariat

Zlotta

Boorjian

Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes

Eur Urol693003102016

26346676

10.1016/j.eururo.2015.08.037

Radkiewicz

Edgren

Johansson

ALV

Jahnson

Häggström

Akre

Lambe

Dickman

Sex Differences in urothelial bladder cancer survival

Clin Genitourin Cancer182634.e62020

31787542

10.1016/j.clgc.2019.10.020

Babjuk

Burger

Compérat

Gontero

Mostafid

Palou

van Rhijn

BWG

Rouprêt

Shariat

Sylvester

European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update

Eur Urol766396572019

31443960

10.1016/j.eururo.2019.08.016

Messing

Tangen

Lerner

Sahasrabudhe

Koppie

Wood

DP Jr

Mack

Svatek

Evans

Hafez

Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial

JAMA319188018882018

29801011

10.1001/jama.2018.4657

Monro

Colón

Yin

Roque

J III

Konda

Gujar

Thummel

Lilge

Cameron

McFarland

Transition metal complexes and photodynamic therapy from a tumor-centered approach: Challenges, opportunities, and highlights from the development of TLD1433

Chem Rev1197978282019

30295467

10.1021/acs.chemrev.8b00211

Sylvester

van der Meijden

APM

Lamm

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials

J Urol168196419702002

12394686

10.1016/S0022-5347(05)64273-5

Lamm

Blumenstein

Crissman

Montie

Gottesman

Lowe

Sarosdy

Bohl

Grossman

Beck

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study

J Urol163112411292000

10737480

Hermans

TJN

Voskuilen

van der Heijden

Schmitz-Dräger

Kassouf

Seiler

Kamat

Grivas

Kiltie

Black

van Rhijn

BWG

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future

Urol Oncol364134222018

29128420

10.1016/j.urolonc.2017.10.014

Shi

Yuan

Chen

Xin

Wang

Shang

Cong

Chen

Puerarin reduces blood pressure in spontaneously hypertensive rats by targeting eNOS

Am J Chin Med4719382019

30612457

10.1142/S0192415X19500022

Shukla

Pandey

Banerjee

Tripathi

Effect of extract of Pueraria tuberosa on expression of hypoxia inducible factor-1α and vascular endothelial growth factor in kidney of diabetic rats

Biomed Pharmacother932762852017

28648975

10.1016/j.biopha.2017.06.045

Satpathy

Patra

Ahirwar

Hussain

Antioxidant and anticancer activities of green synthesized silver nanoparticles using aqueous extract of tubers of Pueraria tuberosa

Artif Cells Nanomed Biotechnol46 (Suppl 3)S71S852018

30043665

10.1080/21691401.2018.1489265

Jearapong

Chatuphonprasert

Jarukamjorn

Miroestrol, a phytoestrogen from Pueraria mirifica, improves the antioxidation state in the livers and uteri of β-naphthoflavone-treated mice

J Nat Med681731802014

23812874

10.1007/s11418-013-0788-6

Ahmad

Khan

Liu

Xue

Nabi

Kumar

Alshwmi

Qarluq

Molecular mechanisms of anticancer activities of Puerarin

Cancer Manag Res1279902020

32021425

10.2147/CMAR.S233567

Lin

Hou

Lin

Hsu

Sheu

Lai

Chen

Lee Chao

Wan

Tsai

Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells

Biochem Biophys Res Commun3786836882009

19013426

10.1016/j.bbrc.2008.10.178

Zhang

Wang

Puerarin 6''-O-xyloside possesses significant antitumor activities on colon cancer through inducing apoptosis

Oncol Lett16555755642018

30344709

10.3892/ol.2018.9364

Bulugonda

Kumar

Gangappa

Beeda

Philip

Muralidhara Rao

Faisal

Mangiferin from Pueraria tuberosa reduces inflammation via inactivation of NLRP3 inflammasome

Sci Rep7426832017

28218280

10.1038/srep42683

Pandey

Yadav

Pandey

Tripathi

Anti-inflammatory effect of Pueraria tuberosa extracts through improvement in activity of red blood cell anti-oxidant enzymes

Ayu342973012013

24501527

10.4103/0974-8520.123131

Srivastava

Pandey

Singh

Tripathi

Anti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets

Biosci Trends133823932019

31597821

10.5582/bst.2019.01181

Shukla

Banerjee

Tripathi

Pueraria tuberosa extract inhibits iNOS and IL-6 through suppression of PKC-α and NF-kB pathway in diabetes-induced nephropathy

J Pharm Pharmacol70110211122018

29770444

10.1111/jphp.12931

Jin

Son

Min

Jung

Choi

Anti-inflammatory and antioxidant activities of constituents isolated from Pueraria lobata roots

Arch Pharm Res358238372012

22644850

10.1007/s12272-012-0508-x

Kim

Lee

Jang

Bae

Kim

Constituents of the roots of Pueraria lobata inhibit formation of advanced glycation end products (AGEs)

Arch Pharm Res298218252006

17121174

10.1007/BF02973900

Sun

Zhang

Cheng

Cao

Qiao

Zhang

Ding

Qiu

New hepatoprotective isoflavone glucosides from Pueraria lobata (Willd.) Ohwi

Nat Prod Res33348534922019

29968479

10.1080/14786419.2018.1484461

Sook Kim

Soo Lee

Sook Kim

Protective effects of Puerariae radix extract and its single compounds on methylglyoxal-induced apoptosis in human retinal pigment epithelial cells

J Ethnopharmacol1525945982014

24486213

10.1016/j.jep.2014.01.008

Sucontphunt

De-Eknamkul

Nimmannit

Dan Dimitrijevich

Gracy

Protection of HT22 neuronal cells against glutamate toxicity mediated by the antioxidant activity of Pueraria candollei var. mirifica extracts

J Nat Med65182011

20658198

10.1007/s11418-010-0442-5

Koirala

Seong

Jung

Choi

Comparative evaluation of the antioxidant and anti-Alzheimer's disease potential of coumestrol and puerarol isolated from Pueraria lobata using molecular modeling studies

Molecules237852018

29597336

10.3390/molecules23040785

Anukulthanakorn

Parhar

Jaroenporn

Kitahashi

Watanbe

Malaivijitnond

Neurotherapeutic effects of Pueraria mirifica extract in early- and late-stage cognitive impaired rats

Phytother Res309299392016

26915634

10.1002/ptr.5595

Tiyasatkulkovit

Malaivijitnond

Charoenphandhu

Havill

Ford

VandeBerg

Pueraria mirifica extract and Puerarin enhance proliferation and expression of alkaline phosphatase and type I collagen in primary baboon osteoblasts

Phytomedicine21149815032014

25442257

10.1016/j.phymed.2014.06.019

Manonai

Chittacharoen

Udomsubpayakul

Theppisai

Effects and safety of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women

Menopause155305352008

18202589

10.1097/gme.0b013e31815c5fd8

Wang

Xie

Sun

Gong

Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation

Phytomedicine207877962013

23639192

10.1016/j.phymed.2013.03.005

Wang

Zheng

Song

Yang

Zhang

In vitro and in vivo anticancer activity of a novel Puerarin nanosuspension against colon cancer, with high efficacy and low toxicity

Int J Pharm4417287352013

23089583

10.1016/j.ijpharm.2012.10.021

Jia

Yang

Puerarin suppresses cell growth and migration in HPV-positive cervical cancer cells by inhibiting the PI3K/mTOR signaling pathway

Exp Ther Med185435492019

31258692

10.3892/etm.2019.7589

Zhang

Liu

Meng

Puerarin inhibits growth and induces apoptosis in SMMC-7721 hepatocellular carcinoma cells

Mol Med Rep10275227582014

25175767

10.3892/mmr.2014.2512

Zhang

Yin

Liu

Meng

Tang

Huang

Gao

Puerarin induces hepatocellular carcinoma cell apoptosis modulated by MAPK signaling pathways in a dose-dependent manner

Anticancer Res37442544312017

28739736

10.21873/anticanres.11837

Xiang

Shan

Jiao

Ren

Lou

Two pairs of diastereoisomeric isoflavone glucosides from the roots of Pueraria lobata

Fitoterapia1441045942020

32298764

10.1016/j.fitote.2020.104594

Shi

Hao

Han

Pang

Dong

Qin

Wang

Zhang

Xia

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Mol Cancer21372022

35130920

10.1186/s12943-022-01517-9

Nandana

Rasyid

Prihantono

Yustisia

Hakim

Bukhari

Prasedya

Cytotoxicity and apoptosis studies of brucein D against T24 bladder cancer cells

Asian Pac J Cancer Prev259219302024

38546074

10.31557/APJCP.2024.25.3.921

Sun

Liu

Tong

Yin

Zhu

Chen

Zhang

Gou

SIRT1 promotes cisplatin resistance in bladder cancer via beclin1 deacetylation-mediated autophagy

Cancers (Basel)161252023

38201552

10.3390/cancers16010125

Mun

Baek

Jeong

Jang

Lee

You

Kim

Yang

Choi

Kim

Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells

Cell Death Discov84502022

36344487

10.1038/s41420-022-01242-8

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method

Methods254024082001

11846609

10.1006/meth.2001.1262

Dong

Guo

Gao

Guan

Niu

Rong

Effect of Puerariae radix flavones on mRNA expression of N-myc downstream regulatory gene 1 in bladder cancer cell line T24

J Environ Health419419432024(In Chinese)

Vanden Berghe

Linkermann

Jouan-Lanhouet

Walczak

Vandenabeele

Regulated necrosis: The expanding network of non-apoptotic cell death pathways

Nat Rev Mol Cell Biol151351472014

24452471

10.1038/nrm3737

Lavrik

Krammer

Regulation of CD95/Fas signaling at the DISC

Cell Death Differ1936412012

22075988

10.1038/cdd.2011.155

Peter

Krammer

The CD95(APO-1/Fas) DISC and beyond

Cell Death Differ1026352003

12655293

10.1038/sj.cdd.4401186

Rehm

Huber

Dussmann

Prehn

Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein

EMBO J25433843492006

16932741

10.1038/sj.emboj.7601295

Cheng

Zhou

Liu

Shapiro

Brauer

Kiefer

Barr

Mountz

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

Science263175917621994

7510905

10.1126/science.7510905

Kantari

Walczak

Caspase-8 and bid: Caught in the act between death receptors and mitochondria

Biochim Biophys Acta18135585632011

21295084

10.1016/j.bbamcr.2011.01.026

Sartorius

Schmitz

Krammer

Molecular mechanisms of death-receptor-mediated apoptosis

Chembiochem220292001

11828422

10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.0.CO;2-X

Kaufmann

Strasser

Jost

Fas death receptor signalling: Roles of Bid and XIAP

Cell Death Differ1942502012

21959933

10.1038/cdd.2011.121

Lin

Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation

Cytokine41182008

18068998

10.1016/j.cyto.2007.09.016

Wajant

Scheurich

TNFR1-induced activation of the classical NF-κB pathway

FEBS J2788628762011

21232017

10.1111/j.1742-4658.2011.08015.x

Karin

Nuclear factor-kappaB in cancer development and progression

Nature4414314362006

16724054

10.1038/nature04870

Luo

Tan

Ricono

Korchynskyi

Zhang

Gonias

Cheresh

Karin

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin

Nature4466906942007

17377533

10.1038/nature05656

Karin

Lin

NF-kappaB at the crossroads of life and death

Nat Immunol32212272002

11875461

10.1038/ni0302-221

Ben-Neriah

Karin

Inflammation meets cancer, with NF-κB as the matchmaker

Nat Immunol127157232011

21772280

10.1038/ni.2060

Baud

Karin

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

Nat Rev Drug Discov833402009

19116625

10.1038/nrd2781

Vazquez-Santillan

Melendez-Zajgla

Jimenez-Hernandez

Martínez-Ruiz

Maldonado

NF-κB signaling in cancer stem cells: A promising therapeutic target?

Cell Oncol (Dordr)383273392015

26318853

10.1007/s13402-015-0236-6

Cao

Jin

Effects of Fas, NF-κB and caspases on microvascular endothelial cell apoptosis induced by TNFα

Chin J Pathophysiol815182001(In Chinese)

Figure 1

Inhibitory effect of PRF on bladder cancer T24 cells. (A) Inhibitory rate of each PRF treatment group on cell viability at each time point. ^*P<0.05. (B) At each time point, the cell viability inhibition rate exhibited a concentration-dependent increase with PRF. PRF, Puerariae radix flavone.

Figure 2

Acridine orange/ethidium bromide staining of T24 cells exposed PRF. (A) Control for 24 h, the yellow arrow indicates viable T24 cells exhibiting green fluorescence with intact plasma membranes. (B) 50 µg/ml and 24 h, yellow arrow indicates early apoptotic cells demonstrating green fluorescence with punctate orange-red fluorescence, along with characteristic morphological changes including cell shrinkage, nuclear condensation, and apoptotic body formation. (C) 100 µg/ml and 24 h, yellow arrow indicates apoptotic cells in early and late stages, exhibiting green fluorescence accompanied by orange-red fluorescence. Early-stage cells show apoptotic body formation, while late-stage cells display plasma membrane disintegration, chromatin fragmentation, and diffuse nuclear orange-red fluorescence. (D) 200 µg/ml and 24 h, the yellow arrow indicates late apoptotic cells exhibiting orange-red fluorescence, characterized by chromatin fragmentation and nuclear disintegration. (E) Control and 48 h, the yellow arrow indicates viable T24 cells exhibiting green fluorescence with intact plasma membranes. (F) 50 µg/ml and 48 h, yellow arrow indicates early apoptotic cells demonstrating green fluorescence with punctate orange-red fluorescence, along with characteristic morphological changes including cell shrinkage, nuclear condensation, and apoptotic body formation. (G) 100 µg/ml and 24 h, yellow arrow indicates apoptotic cells in early and late stages, exhibiting green fluorescence accompanied by orange-red fluorescence. Early-stage cells show apoptotic body formation, while late-stage cells display plasma membrane disintegration, chromatin fragmentation and diffuse nuclear orange-red fluorescence. (H) 200 µg/ml and 48 h, the yellow arrow indicates late apoptotic cells exhibiting orange-red fluorescence, characterized by chromatin fragmentation and nuclear disintegration. Magnification, x200. PRF, Puerariae radix flavone.

Figure 3

Fragmentation of genomic DNA in T24 cells treated with PRF at concentrations of 0, 50, 100, and 200 µg/ml for 24 or 48 h. Compared with the 0 µg/ml PRF group, no significant changes were observed in the other treatment groups, and no characteristic DNA ladder was detected. PRF, Puerariae radix flavone.

Figure 4

Effects of PRF on the expression of apoptosis-related genes in T24 cells. T24 cells were treated with PRF (0, 50, 100 and 200 µg/ml) for 24 or 48 h. The mRNA levels of (A) FAS, (B) FASL, (C) TNFα, (D) TNFR1, (E) CASP3, (F) NF-κB, (G) BCL2 and (H) BAX were assessed by quantitative PCR (normalized to GAPDH). ^*P<0.05. PRF, Puerariae radix flavones; CASP3, cysteinyl aspartate-specific protease-3.

Figure 5

PRF regulates intracellular and secreted levels of FAS and TNF-α in T24 cells. T24 cells were exposed to PRF (0, 50, 100 or 200 µg/ml) for 24 or 48 h. (A) FAS levels in cell lysate (intracellular proteins). (B) Secreted FAS levels in conditioned medium. (C) TNF-α levels in cell lysates (intracellular proteins). (D) Secreted TNF-α levels in conditioned medium. Protein quantification was performed by ELISA. ^*P<0.05. PRF, Puerariae radix flavone.

Figure 6

Mechanism of apoptosis. Apoptotic signaling primarily occurs via two pathways: the extrinsic death receptor pathway and the intrinsic mitochondrial pathway. In T24 cells, PRF induces apoptosis predominantly by activating FAS and TNFR1, thereby initiating the death receptor pathway. This ultimately leads to the activation of CASPASE3, resulting in characteristic biochemical and morphological changes characteristic of programmed cell death. Concurrently, NF-κB participates in the regulation of this apoptotic pathway. TNFR, tumor necrosis factor receptor; TRAF, TNFR-Associated Factor; TRADD, TNFR-associated death domain; RIP, receptor-interacting protein; IKK, IκB kinase; tBid, truncated Bid; PRF, Puerariae radix flavone.

Table I

Primer sequences for reverse transcription-quantitative PCR.

Gene	Primer sequence, 5'→3'	Product length, bp
GAPDH	F:GCATCCTGGGCTACACTG	103
	R:TGGTCGTTGAGGGCAAT
BAX	F:CGGAACTGATCAGAACCATCA	97
	R:AGGAGTCTCACCCAACCA
BCL2	F:GTGGATGACTGAGTACCTGAAC	125
	R:GAGACAGCCAGGAGAAATCAA
CASP3	F:CTCCACAGCACCTGGTTATT	106
	R:AAATTCAAGCTTGTCGGCATAC
NF-kB	F:GGTGCGGCTCATGTTTACAG	85
	R:GATGGCGTCTGATACCACGG
TNFR1	F:CTCCAAATGCCGAAAGGAAATG	100
	R:ATAATGCCGGTACTGGTTCTTC
TNFα	F:CCAGGGACCTCTCTCTAATCA	106
	R:TCAGCTTGAGGGTTTGCTAC
FAS	F:GTGATGAAGGACATGGCTTAGA	115
	R:GGGTCACAGTGTTCACATACA
FASL	F:CATTTAACAGGCAAGTCCAACTC	105
	R:CACAAGGCCACCCTTCTTAT

F, forward; R, reverse.